Patents by Inventor Matthew Dong

Matthew Dong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for high-throughput activation screening to boost T cell effector function
    Patent number: 12497611
    Abstract: The present invention includes dead-guide RNA (dgRNA) libraries and methods of use in immunology and immunotherapy thereof. Also provided are engineered primary or chimeric antigen receptor (CAR) T cells that overexpress Prodh2, Ccnblip1, Sreklip1, or Wdr37 or a fragment thereof, and methods of use in immunology and immunotherapy thereof.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: December 16, 2025
    Assignee: Yale University
    Inventors: Sidi Chen, Ryan D. Chow, Lupeng Ye, Matthew Dong, Jonathan Park, Lei Peng
  • Compositions for identification of membrane targets for enhancement of T cell activity against cancer
    Patent number: 12297428
    Abstract: The present invention includes compositions and methods for identification of membrane targets for enhancement of T cell activity against a disease, disorder or condition, and/or enhancing T cell anti-tumor activity in a subject in need thereof. In some embodiments, the disease is cancer. In further embodiments, the cancer is glioblastoma (GBM) or breast cancer.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: May 13, 2025
    Assignee: Yale University
    Inventors: Sidi Chen, Lupeng Ye, Jonathan Park, Matthew Dong, Ryan D. Chow
  • COMPOSITIONS AND METHODS FOR VACCINATION AGAINST PATHOGENIC CORONAVIRUS SPECIES AND VARIANTS
    Publication number: 20250134987
    Abstract: The current disclosure includes coronavirus vaccines that protect against pathogenic coronavirus species, as well as their variants. In certain embodiments, SARS-CoV-2 variant specific and multivalent coronavirus vaccines are described. The vaccines typically include a modified mRNA which encodes at least one coronavirus derived immunogen, such as a spike protein or a fragment thereof. The mRNA can be encapsulated into lipid nanoparticles or other carriers and formulated as pharmaceutical compositions which can be used to generate an immune response to coronavirus in a subject. The vaccines can be used to elicit potent B and T cell responses against SARS-CoV-2 variants and to confer protective immunity against SARS-CoV-2, as well as other pathogenic coronavirus species such as SARS-CoV and/or MERS-CoV.
    Type: Application
    Filed: October 14, 2022
    Publication date: May 1, 2025
    Inventors: Sidi Chen, Lei Peng, Zhenhao Fang, Jonathan Park, Matthew Dong, Xiaoyu Zhou, Paul Renauer
  • Platform for T lymphocyte genome engineering and in vivo high-throughput screening thereof
    Patent number: 11926839
    Abstract: The present invention includes compositions and methods for T cell genome editing and screening in vivo. In certain aspects, the invention includes an sgRNA library for genome-scale mutagenesis.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: March 12, 2024
    Assignee: YALE UNIVERSITY
    Inventors: Sidi Chen, Matthew Dong
  • Compositions and Methods for Identification of Membrane Targets for Enhancement of T cell Activity Against Cancer
    Publication number: 20220340898
    Abstract: The present invention includes compositions and methods for identification of membrane targets for enhancement of T cell activity against a disease, disorder or condition, and/or enhancing T cell anti-tumor activity in a subject in need thereof. In some embodiments, the disease is cancer. In further embodiments, the cancer is glioblastoma (GBM) or breast cancer.
    Type: Application
    Filed: July 31, 2019
    Publication date: October 27, 2022
    Inventors: Sidi Chen, Lupeng Ye, Jonathan Park, Matthew Dong, Ryan D. Chow
  • A Platform for T Lymphocyte Genome Engineering and In Vivo High-Throughput Screening Thereof
    Publication number: 20220259616
    Abstract: The present invention includes compositions and methods for T cell genome editing and screening in vivo. In certain aspects, the invention includes an sgRNA library for genome-scale mutagenesis.
    Type: Application
    Filed: April 17, 2018
    Publication date: August 18, 2022
    Inventors: Sidi Chen, Matthew Dong
  • Compositions and Methods for Efficacy Enhancement of T-Cell Based Immunotherapy
    Publication number: 20220017715
    Abstract: The present invention includes compositions and methods for enhancing T cell based immunotherapy. In certain aspects, the invention includes modified T cells and inhibitors of Dhx37 for use in enhancing T cell based immunotherapy and treating cancer.
    Type: Application
    Filed: June 22, 2018
    Publication date: January 20, 2022
    Inventors: Sidi Chen, Matthew Dong
  • Compositions and Methods for High-Throughput Activation Screening to Boost T Cell Effector Function
    Publication number: 20210269794
    Abstract: The present invention includes dead-guide RNA (dgRNA) libraries and methods of use in immunology and immunotherapy thereof. Also provided are engineered primary or chimeric antigen receptor (CAR) T cells that overexpress Prodh2, Ccnblip1, Sreklip1, or Wdr37or a fragment thereof, and methods of use in immunology and immunothereapy thereof.
    Type: Application
    Filed: August 15, 2019
    Publication date: September 2, 2021
    Inventors: Sidi Chen, Ryan D. Chow, Lupeng Ye, Matthew Dong, Jonathan Park, Lei Peng